Skip to main content
Top
Published in: Infection 4/2014

01-08-2014 | Case Report

Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis

Authors: R. Gagliardini, M. Fabbiani, S. Fortuna, E. Visconti, P. Navarra, R. Cauda, M. Colafigli, A. De Luca, E. M. Trecarichi, S. Di Giambenedetto

Published in: Infection | Issue 4/2014

Login to get access

Abstract

Etravirine is metabolized by three cytochrome P450 enzymes that are in turn induced by rifampin. Consequently, co-administration of etravirine and rifampin is not recommended. To date, however, no clinical studies exploring the drug–drug interaction of this combination have been conducted. Here we report two cases of off-label etravirine use concurrently with antitubercular treatment, dictated by the unavailability of other treatments. Plasma drug concentrations were monitored by regular measurements. Our results appear to confirm the increased metabolism of etravirine through the induction of cytochrome P450 enzymes, but the adequacy of drug levels in all of the measurements and subsequent virological suppression suggest that this drug interaction may not be clinically relevant.
Literature
4.
go back to reference Fabbiani M, Di Giambenedetto S, Bracciale L, et al. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 2009;64:109–17. Fabbiani M, Di Giambenedetto S, Bracciale L, et al. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 2009;64:109–17.
5.
go back to reference Bazzoli C, Jullien V, Le Tiec C, et al. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet. 2010;49(1):17–45.PubMedCrossRef Bazzoli C, Jullien V, Le Tiec C, et al. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet. 2010;49(1):17–45.PubMedCrossRef
6.
go back to reference Kakuda TN, Schöller-Gyüre M, Workman C, et al. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther. 2008;13:655–61.PubMed Kakuda TN, Schöller-Gyüre M, Workman C, et al. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther. 2008;13:655–61.PubMed
7.
go back to reference Kakuda TN, Scholler-Gyure M, De Smedt G, et al. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med. 2009;10:173–81.PubMedCrossRef Kakuda TN, Scholler-Gyure M, De Smedt G, et al. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med. 2009;10:173–81.PubMedCrossRef
8.
go back to reference Kakuda T, Sekar V, Vis P, et al. Pharmacokinetics and pharmacodynamics of darunavir and etravirine in HIV-1-infected, treatment-experienced patients in the Gender, Race, and Clinical Experience (GRACE) trial. AIDS Res Treat. 2012;2012:186987. doi: 10.1155/2012/186987 Kakuda T, Sekar V, Vis P, et al. Pharmacokinetics and pharmacodynamics of darunavir and etravirine in HIV-1-infected, treatment-experienced patients in the Gender, Race, and Clinical Experience (GRACE) trial. AIDS Res Treat. 2012;2012:186987. doi: 10.​1155/​2012/​186987
9.
go back to reference Tiraboschi JM, Niubo J, Vila A, et al. Etravirine concentrations in CSF in HIV-infected patients. J Antimicrob Chemother. 2012;67:1446–8.PubMedCrossRef Tiraboschi JM, Niubo J, Vila A, et al. Etravirine concentrations in CSF in HIV-infected patients. J Antimicrob Chemother. 2012;67:1446–8.PubMedCrossRef
Metadata
Title
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis
Authors
R. Gagliardini
M. Fabbiani
S. Fortuna
E. Visconti
P. Navarra
R. Cauda
M. Colafigli
A. De Luca
E. M. Trecarichi
S. Di Giambenedetto
Publication date
01-08-2014
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2014
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-014-0599-z

Other articles of this Issue 4/2014

Infection 4/2014 Go to the issue